ERIS

ERIS LIFESCIENCES

Mid Cap BSE: 540596 NSE: ERIS
₹675.00
14.85 (2.25%)
As on 10 December, 2022 | 08:44

Eris Lifesciences Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in ERIS LIFESCIENCES

Start SIP

Eris Lifesciences Share Price

Eris Lifesciences Share Returns

  • Over 1 Month -4.83%
  • Over 3 Month -3.89%
  • Over 6 Month 3.7%
  • Over 1 Year -7.49%

Eris Lifesciences Key Statistics

P/E Ratio 23.2
PEG Ratio 7.7
Market Cap Cr 9,179
Price to Book Ratio 4.8
EPS
Dividend 1.1
Relative Strength Index 46.39
Money Flow Index 37.81
MACD Signal -11.86
Average True Range 15.76

Eris Lifesciences Investment Rating

  • Master Rating:
  • Eris Lifesciences has an operating revenue of Rs. 1,497.20 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 33% is great, ROE of 21% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 21% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 61 which is a FAIR score but needs to improve its earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 158 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Eris Lifesciences Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 350322277300323306257
Operating Expenses Qtr Cr 214203181182186184163
Operating Profit Qtr Cr 14112610212313712394
Depreciation Qtr Cr 16151514121110
Interest Qtr Cr 7711100
Tax Qtr Cr 912810131117
Net Profit Qtr Cr 115968710412010769

Eris Lifesciences Technicals

EMA & SMA

Current Price
675.
14.85 (2.25%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 676.76
  • 50 Day
  • 690.36
  • 100 Day
  • 693.05
  • 200 Day
  • 693.58
  • 20 Day
  • 675.16
  • 50 Day
  • 703.08
  • 100 Day
  • 696.55
  • 200 Day
  • 688.01

Eris Lifesciences Resistance and Support

PIVOT
₹662.29
Resistance
First Resistance 665.57
Second Resistance 670.99
Third Resistance 674.27
RSI 46.39
MFI 37.81
MACD Single Line -11.86
MACD -11.2
Support
First Resistance 656.87
Second Resistance 653.59
Third Resistance 648.17

Eris Lifesciences Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 71,696 3,721,739 51.91
Week 69,235 5,578,972 80.58
1 Month 43,320 2,830,538 65.34
6 Month 47,724 2,939,787 61.6

Eris Lifesciences Result Highlights

Eris Lifesciences Synopsis

NSE-Medical-Biomed/Biotech

Eris Lifesciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1215.73 Cr. and Equity Capital is Rs. 13.59 Cr. for the Year ended 31/03/2022. Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867.
Market Cap 9,194
Sales 1,271
Shares in Float 6.53
No of funds 118
Yield 1.09
Book Value 4.79
U/D Vol ratio 0.5
LTDebt / Equity
Alpha -0.03
Beta 0.52

Eris Lifesciences

Owner NameSep-22Jun-22Mar-22Dec-21
Promoters 52.29%52.3%52.66%
Mutual Funds 10.38%10.36%10.11%
Foreign Portfolio Investors 15.39%15.35%13.31%
Financial Institutions/ Banks
Individual Investors 21.26%21.34%23.14%
Others 0.68%0.65%0.78%

Eris Lifesciences Management

Name Designation
Mr. Amit Bakshi Chairperson & Managing Director
Mr. Krishnakumar Vaidyanathan COO & Executive Director
Mr. Inderjeet Singh Negi Executive Director
Mr. Kaushal Shah Executive Director
Mr. Rajeev Dalal Independent Director
Mr. Vasudevan Sujesh Independent Director
Ms. Kalpana Unadkat Independent Director
Mr. Prashant Gupta Independent Director

Eris Lifesciences Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Eris Lifesciences Corporate Action

Date Purpose Remarks
2022-10-20 Quarterly Results
2022-08-05 Quarterly Results & Interim Dividend
2022-05-03 Audited Results
2022-01-28 Quarterly Results
2021-10-29 Quarterly Results
Date Purpose Remarks
2022-08-16 INTERIM Rs.7.35 per share(735%)Interim Dividend
2021-08-06 INTERIM Rs.6.01 per share(601%)Interim Dividend

Eris Lifesciences MF Shareholding

Name Amount(cr)
UTI Flexi Cap Fund Regular Plan Growth 26102
Kotak Emerging Equity Scheme Growth 23224
Aditya Birla Sun Life Equity Hybrid '95 Fund Growth 7808
Franklin India Smaller Companies Fund Growth 7422
UTI Value Opportunities Fund Regular Plan Growth 7194

Eris Lifesciences FAQs

What is Share Price of Eris Lifesciences ?

Eris Lifesciences share price is ₹675 As on 10 December, 2022 | 08:30

What is the Market Cap of Eris Lifesciences ?

The Market Cap of Eris Lifesciences is ₹9179.4 Cr As on 10 December, 2022 | 08:30

What is the P/E ratio of Eris Lifesciences ?

The P/E ratio of Eris Lifesciences is 23.2 As on 10 December, 2022 | 08:30

What is the PB ratio of Eris Lifesciences ?

The PB ratio of Eris Lifesciences is 4.8 As on 10 December, 2022 | 08:30

Q2FY23